SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VRAL - Viral Genetics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen2/11/2011 3:30:15 PM
   of 35
 
More from Biotech Stock Review:
Quote:
Today we (Biotech Stock Review) issued a press release announcing that are updating coverage on Viral Genetics (VRAL) as well as to note that we will be issuing a detailed research report before the quarter is out (a more reasonable time table).
...
What was anticipated was:

1. Appearance on the Wide World of Stocks in December.
2. Initiation of Clinical Trials at Scott & White Cancer Treatment Center in Temple, Texas.
3. Full report issued by the Biotech Stock Review in December.
4. Full report issued by Research 2.0 in January.
5. Report on progress of recently formed VG Energy, a majority owned subsidiary.

What actually happened was (December and until last week):

1. Appearance on the Wide World of Stocks in December.
2. Funding of Clinical Trials at Scott & White Cancer Treatment Center in Temple, Texas (a huge surprise).
3. Full report issued by the Biotech Stock Review in December (okay make that late February, early March)
4. Full report issued by Zacks with a $0.15 price target.
5. Full report issued by Research 2.0 with varying scenario price targets ranging from $0.43 to $3.00.
6. Four mentions in Biotech and Health Care News.
7. Detailed coverage of VG Energy in Energy Boom magazine.
8. Settlement of a lawsuit and subsequent reacquiring of their South African to HIV/AIDS technology rights.
9. A wonderfully detailed shareholder letter from management
10. And finally a gradually increasing share price (up 53%) which results in favorable technical readings.
...
So we thought, "like ourselves, probably everyone else has forgotten all of the amazing (and enlightening) amount of information buried in that single press release issued nearly four months ago -- so lets just "cut-n-paste," and re-release it in "report" format and use a bold font (an uncommon practice in press releases) what we consider was jaw dropping, of which there was plenty.

You can find the "update" here: www.biotechstockreview.com biotechstockreview.ning.com
.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News